Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 32,914 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo-Control Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636
View directory record Official record
Conditions
Change in Bone Mineral Density, Bone Loss
Interventions
drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
1,536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
27
States / cities
Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack

NCT01230411
View directory record Official record
Conditions
Episodic Migraine
Interventions
saline placebo, Ibuprofen
Other · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 21, 2026, 9:36 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy-Induced Immune Modulation: Part III

NCT03643744
View directory record Official record
Conditions
Actinic Keratosis, Photodynamic Therapy
Interventions
Celecoxib 200mg, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 3 Interventional

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

NCT00352144
View directory record Official record
Conditions
Primary Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
21 Years to 64 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
58
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

NCT01381887
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 21, 2026, 9:36 AM EDT
Terminated Phase 4 Interventional Results available

Steroid Use in Non-RSV Bronchiolitis

NCT04221087
View directory record Official record
Conditions
Bronchiolitis, Viral
Interventions
Placebos, Dexamethasone Oral
Drug
Lead sponsor
Allison Williams
Other
Eligibility
1 Day to 2 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 21, 2026, 9:36 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

NCT01151787
View directory record Official record
Conditions
Chronic Migraine
Interventions
cyclobenzaprine hydrochloride, placebo
Drug
Lead sponsor
Kennedy Medical Group
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cherry Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 21, 2026, 9:36 AM EDT
Not listed Phase 2 Interventional

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

NCT02407600
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Vomiting, Nausea, Emesis
Interventions
FOSAPREPITANT (Emend), Placebo
Drug
Lead sponsor
Ajeet Gajra
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 2 Interventional

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

NCT00993707
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CTX-100 (formerly ETX-100) (hyaluronic acid)
Drug
Lead sponsor
Turino, Gerard, M.D.
Individual
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

A Study of ARRY-371797 in Patients With Rheumatoid Arthritis

NCT00729209
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ARRY-371797, p38 inhibitor; oral, Placebo; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Tuscaloosa, Alabama • Peoria, Arizona • Little Rock, Arkansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 3 Interventional

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

NCT02255799
View directory record Official record
Conditions
Traumatic Brain Injury, Memory Deficits
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

NCT01663532
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
43
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 3 Interventional

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

NCT05047263
View directory record Official record
Conditions
Non-diabetic Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
57
States / cities
Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

NCT02458287
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 4 Interventional

Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

NCT00693121
View directory record Official record
Conditions
Traumatic Brain Injury, Posttraumatic Confusional State, Delirium
Interventions
Amantadine hydrochloride, Placebo capsule
Drug
Lead sponsor
Methodist Rehabilitation Center
Other
Eligibility
16 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 3 Interventional

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

NCT00422214
View directory record Official record
Conditions
Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 21, 2026, 9:36 AM EDT
Recruiting Phase 3 Interventional

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006
View directory record Official record
Conditions
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 9:36 AM EDT
Active, not recruiting Phase 3 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Granada Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652
View directory record Official record
Conditions
Heart Failure
Interventions
HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 21, 2026, 9:36 AM EDT
Active, not recruiting Phase 2 Interventional

Caffeine Use in the Management of Preterm Infants

NCT06327152
View directory record Official record
Conditions
Apnea of Prematurity
Interventions
Caffeine, Sterile Water Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Week to 40 Weeks
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Gabapentin for Abstinence Initiation in Alcohol Dependence

NCT01141049
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 21, 2026, 9:36 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 2 Interventional

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00104377
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
Overland Park, Kansas • North Dartmouth, Massachusetts • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 21, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 21, 2026, 9:36 AM EDT